Your Messages Inbox
Your Article Summary
See Latest ArticlesImmunoGen, Inc. Announces Completion of Public Offering of Common Stock
ImmunoGen, Inc., 06/24/09
ImmunoGen, Inc. , a biopharmaceutical company that develops targeted anticancer therapeutics, announced the completion of its previously reported public offering of 5,750,000 shares of common stock. The Company received net proceeds, after underwriting discounts and commissions and estimated expenses, of approximately $38.0 million.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09
Article Search
Sponsor